Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]GTP1 is a deuterated small-molecule positron emission tomography (PET) imaging agent developed for the in vivo detection of tau neurofibrillary tangles in the brains of patients with Alzheimer's disease. It binds with high affinity and selectivity to aggregated tau protein without significant off-target binding to β-amyloid plaques or monoamine oxidase B (MAO-B), making it a specific radiopharmaceutical for visualizing tau pathology. The tracer demonstrates favorable dosimetry and brain kinetics in humans and is used primarily as a diagnostic tool to assess tau burden longitudinally in Alzheimer's disease research and clinical trials[2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]GTP1.